PLoS ONE (Jan 2021)

Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol.

  • Victor Arévalos,
  • Luis Ortega-Paz,
  • Diego Fernandez-Rodríguez,
  • Víctor Alfonso Jiménez-Díaz,
  • Jordi Bañeras Rius,
  • Gianluca Campo,
  • Miguel Rodríguez-Santamarta,
  • Armando Pérez de Prado,
  • Antonio Gómez-Menchero,
  • José Francisco Díaz Fernández,
  • Claudia Scardino,
  • Nieves Gonzalo,
  • Alberto Pernigotti,
  • Fernando Alfonso,
  • Ignacio Jesús Amat-Santos,
  • Antonio Silvestro,
  • Alfonso Ielasi,
  • José María de la Torre,
  • Gabriela Bastidas,
  • Josep Gómez-Lara,
  • Manel Sabaté,
  • Salvatore Brugaletta,
  • CV COVID-19 Registry Investigators

DOI
https://doi.org/10.1371/journal.pone.0255263
Journal volume & issue
Vol. 16, no. 7
p. e0255263

Abstract

Read online

BackgroundPatients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes.Study and designThis is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than 18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to August 2020. Patients will be classified into two groups, according to the results of the RT-PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes will be compared between the two groups. Events will be adjudicated by an independent clinical event committee.ConclusionThe results of this registry will contribute to a better understanding of the long-term cardiovascular implications of the COVID19.